Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Tango Therapeutics, Inc. (TNGX) Misses Q3 EPS by 7c
November 4, 2025 9:04 AM ESTTango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.14), $0.07 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $53.81 million versus the consensus estimate of $53.8 million.
For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.
... More